|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
SHORT WHITE CANDLE
Trading: BUY @ $227.4
Signal Strength: WEAK
Indicator MUST BE USED in additional to another technical indicator to confirmation for trading position. Indicator can be applied to the short term timeframe but is only able to give and indication of the strength of the buyers versus sellers at the market close. This Japanese candlestick indicator can provide guidance on the short term battle between sellers and buyers from the companies recent trading.
CSL (ASX:CSL) has formed a Short White candlestick. This means, CSL has limited price movement derived from weak buying pressure. Given the limited timeframe in which signal has formed, further confirmation is required through volume and additional technical indicators.
This candlestick implies a relatively weak buying pressure with a limited price movement.
Calculation: Short White Candlestick:
1) The body of the candlestick is white and small.
PROFILE: CSL (CSL.AX)
Stock Exchange: ASX
Ticker Codes: | CSL.AX | ASX:CSL |
CSL Limited engages in the research, development, manufacture, marketing, and distribution of biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, and internationally. It operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of bleeding disorders, including hemophilia and von Willebrand disease, primary and secondary immunodeficiency's, hereditary angioedema, neurological disorders, and inherited respiratory diseases. Its products are also used to prevent haemolytic diseases in newborns and infections in solid organ transplant recipients, as well as specific infections; and for urgent warfarin reversal in patients with acute major bleeding, as well as victims of trauma, shocks, and burns. In addition, this segment operates approximately 180 human blood plasma collection centers. Further, it conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and offers influenza vaccines. It also provides in-licensed vaccines and specialty pharmaceuticals; manufactures and markets diagnostics for immunohematology laboratories; and supplies a range of products, including antivenoms and Q fever vaccines. The company was founded in 1916 and is headquartered in Parkville, Australia.
|CCP Credit Corp||27.27||13.3||452,171||0||BULLISH|
|ATL ASX 20||0.43||10.4||117,204||0||BULLISH|
|SUL Super Cheap Auto||9.75||7.9||2,023,965||1||BULLISH|
|SGR The Star Entertainment||3.79||5.9||14,342,914||0||BULLISH|
|AHG Advance Healthcare||3.21||4.6||663,989||0||BULLISH|